Business plans
SBIR commercialization plan: what must it contain, and how do USDA, NIH and DOE requirements differ?
A Phase II application under the SBIR and STTR programs carries a commercialization plan: the business case for turning the funded research into a product. USDA writes the requirement into its regulation at 7 CFR 3403.8, NIH caps the plan at 12 pages, and DOE asks for a 15-page plan with a five-year cash flow pro forma and up to five letters of support. The sections overlap with a business plan, in each agency's format.

What is an SBIR commercialization plan?
The part of a Phase II application that explains how the innovation will become a product with buyers and revenue. DOE calls it the business case and notes that commercialization is a statutory goal of the SBIR/STTR programs.
The NIFA page on commercialization plans, part of USDA's SBIR/STTR program, opens with the purpose: "The goal of any successful SBIR/STTR project is commercialization of your innovation." It quotes SBA's definition of commercialization as "developing, producing and delivering products, processes, technologies or services."
The Department of Energy calls the Phase II Commercialization Plan the applicant's business case. Its 2025 specifications state: "Commercialization is a statutory goal of the SBIR/STTR programs." The same materials state that Congress wants to see the return on taxpayer dollars.
Each agency publishes its own format. USDA sets out the elements in a regulation, NIH in a guide from the National Institute on Drug Abuse, and DOE in a set of specifications for its Phase II applications. The sections below compare them, then go through the parts that every version shares: market, intellectual property, finance and letters of support.
When does an application need a commercialization plan?
At Phase II. USDA's regulation requires a plan in each SBIR Phase II proposal moving toward commercialization; NIFA says Phase I does not require one. NIH requires it for Phase II, Fast-Track and Phase II Competing Renewal applications.
Under 7 CFR 3403.8, which governs USDA SBIR Phase II proposals, "A succinct commercialization plan must be included in each SBIR Phase II proposal moving toward commercialization." The section begins with the reason Phase II proposals are longer: "Since Phase II is the principal research and development effort, proposals should be more comprehensive" than Phase I proposals.
The NIFA page states that "a commercialization plan is not a requirement for Phase I applications," and advises applicants to start considering one for Phase II. It adds that a Phase I application is stronger when it shows commercialization planning.
The NIH guide states that Phase II, Fast-Track and Phase II Competing Renewal applications must include a succinct commercialization plan. It notes that Phase III, the commercial stage, is pursued with funds other than SBIR or STTR awards. DOE's materials state that all Phase II applications, including Phase IIA, IIB and IIC, require an updated commercialization plan.
What does USDA require under 7 CFR 3403.8?
Six elements: company information, customer and competition, market, intellectual property, financing for Phase III, and assistance and mentoring. The market element asks for market size and estimated market share after the first year of sales and after five years.
Paragraph (a)(7) of 7 CFR 3403.8 lists the elements a USDA plan may include. Company information covers "Focused objectives/core competencies; size; specialization area(s); products with significant sales; and history of previous Federal and non-Federal funding; regulatory experience; and subsequent commercialization."
Customer and competition asks for a "Clear description of key technology objectives, current competition, and advantages compared to competing products or services; description of hurdles to acceptance of the innovation." Market asks for "Milestone, target dates, analyses of market size, and estimated market share after first year sales and after five years; explanation of plan to obtain market share."
Intellectual property covers patent status, technology lead, trade secrets or other proof of a plan to achieve protection sufficient "to realize the commercialization state and attain at least a temporary competitive advantage." Financing is a single line: "Plans for securing necessary funding in Phase III."
The last element is particular to the regulation: assistance and mentoring, "Plans for securing needed technical or business assistance through mentoring, partnering, or through arrangements with state assistance programs, Small Business Development Centers, Federally-funded research laboratories, manufacturing extension Partnership Centers, or other assistance providers." The eCFR text was up to date as of July 13, 2026.
Which sections does the NIFA page list for a Phase II plan?
Project introduction and expected outcomes, company information, the market with customers and competition, intellectual property, revenue stream and financing. The market section includes a schedule of funding needs through commercialization.
The NIFA page, last updated on July 2, 2025, lists six areas that a Phase II plan should cover. "Project Introduction and Expected Outcomes" describes the project, the need it addresses and its commercial applications. "Company Information" covers corporate objectives, core competencies, size and sales history and the vision for sustainable growth.
"The Market, Customer and Competition" covers market size, the customer profile, advantages over alternatives, hurdles to adoption, the marketing and sales approach, competitors and a schedule of funding needs through commercialization. "Intellectual Property" explains how the innovation will be protected, including steps to gain a temporary edge, and the company's track record.
"Revenue Stream" describes how revenue will be generated, the assumptions behind the projections and whether revenue will support profitability over the product's life cycle. "Financing" shows a plan for Phase III funding: a commitment letter, a letter of intent, a support letter or a specific funding plan whose progress is reported in the Phase II progress report.
The NIFA list adds two items to the regulation's six: a revenue stream with stated assumptions and an introduction that ties the project to a need. A USDA applicant who follows both documents covers all eight topics.
What does NIH expect, and how long can the plan be?
No more than 12 pages in nine sections lettered A through I: value of the project, company, market and competition, intellectual property, regulatory strategy, finance plan, production and marketing, revenue stream, and risk analysis.
The NIH guide, "Writing a Good Commercialization Plan: Suggestions for SBIR/STTR Applicants," sets the length: a document "no longer than 12 pages." It is divided into sections A through I.
Section A, Value of the SBIR/STTR Project, states the commercial goal, the problem the project addresses, its importance and its advantages over competing products, with societal, educational and scientific impacts. Section B, Company Overview, covers the company's origins, corporate objectives, core competencies, past federal and non-federal funding, regulatory experience and plans to grow into a commercial entity; for very small teams it focuses on the team's commercialization capabilities.
Section C covers market size and needs, customer segments, competitors, collaborators, the product's advantages and hurdles to adoption. Section D, Intellectual Property Protection, explains which patents protect the work, who owns them and the plan for filing or licensing. Section E is Regulatory Strategy, Section G Production and Marketing Plan and Section I Risk Analysis and Mitigation Strategy.
Section F, Finance Plan, estimates financing by phase, with the timing of financial events and milestones and evidence of funding commitments such as letters of commitment or intent. Section H, Revenue Stream, explains how the company will earn money from the product: direct sales, distributors, joint ventures, licensing or services, and how revenue risk is spread across products.
What did DOE change in its Phase II plan specifications in 2025?
DOE's plan has four sections with more detailed specifications; the ROI worksheet is no longer required, the pro forma templates include cash flow and letters of support are limited to five. The plan runs 15 pages in one PDF.
DOE's 2025 materials announce that the Phase II Commercialization Plan specifications have been updated. The plan has four sections: Market Opportunity, Company/Team, Competition/IP and Finance and Revenue Model. The ROI worksheet is no longer required, the pro forma templates now incorporate cash flow, and letters of support are limited to five.
The applicant uploads one PDF with the 15-page plan, up to five letters of support and the pro forma. Letters of support and the cash flow pro forma do not count toward the page limit. The pro forma covers five years: the two-year Phase II period and three years after the award.
DOE tells applicants to write for the reviewer in narrative prose, not in a question-and-answer format. Its materials note that reviewers of the commercialization plan are business generalists, so the plan avoids jargon and states its assumptions with the evidence behind them. DOE evaluates commercialization under its impact criteria.
The Company/Team section asks for the company's origins, corporate structure, headcount projections and three years of revenue by source, an assessment of whether the company's assets are sufficient, the commercialization experience of key personnel, gaps in the team and non-technical risks.
How should the market section of the plan be built?
Around named customers and their needs, market size in customers and revenue, a growth rate and the share the company can win. USDA asks for share after the first year of sales and after five years.
DOE's Market Opportunity section defines the target customers and their critical needs, estimates market size in number of customers and in revenue, gives growth as a compound annual growth rate and describes the business model and the route to market. It also asks for any societal, educational or scientific benefits.
USDA's regulation asks for milestones and target dates, an analysis of market size, the estimated market share after first-year sales and after five years, and an explanation of the plan to obtain that share. The NIH guide asks for market size and needs and the customer segments, and the NIFA page adds the customer profile and the marketing and sales approach.
The numbers need sources a reviewer can open. A reviewer can check a market size taken from a dated public dataset or a named industry study, a share estimate tied to a sales plan and a list of the customers interviewed; a round figure without a source cannot be checked. DOE's materials cite customer discovery and letters of support as evidence that validates the plan.
What must the intellectual property section say?
What protects the innovation now, what protection is still needed and what competing rights could block it. DOE asks for the closest competing IP that threatens freedom to operate; USDA asks for patent status, technology lead and trade secrets.
USDA's regulation asks for patent status, technology lead, trade secrets or other proof of a plan for sufficient protection and at least a temporary competitive advantage. The NIFA page asks how the innovation will be protected, including steps to gain a temporary edge, and for the company's track record.
DOE's Competition/IP section names competitors and substitutes and compares them with the innovation in numbers. It explains the competitive advantage, describes the existing intellectual property and the intellectual property still needed, and identifies the closest competing IP that threatens freedom to operate.
The NIH guide asks which patents protect the work, who owns them and how the company plans to file or license so that competitors do not get there first. Where the research started at a university, the section answers the NIH question on ownership by stating who holds the patents and whether the company has a license.
What do the finance plan and the revenue model have to show?
How the company will fund the stages after Phase II, from which sources and when, and how the product will earn money. DOE asks for a milestone roadmap and a five-year cash flow pro forma.
DOE's Finance and Revenue Model section asks for a roadmap driven by milestones, with timing, funding levels and funding sources, an explanation of cost drivers and of how shortfalls will be covered, and a five-year cash flow pro forma that shows when first revenues are expected and the total revenue over five years. DOE warns against plans that only list technical milestones.
USDA's regulation asks for "Plans for securing necessary funding in Phase III." The NIFA page describes the evidence: a commitment letter, a letter of intent, a support letter or a specific funding plan whose progress is reported in the Phase II progress report. The NIH finance plan estimates financing by phase with the timing of financial events and evidence of commitments.
The revenue model is a separate question from funding. NIFA asks for the assumptions behind revenue projections and whether revenue will support profitability over the product's life cycle; NIH lists direct sales, distributors, joint ventures, licensing and services as ways to earn revenue and asks how revenue risk is spread across products.
A five-year cash flow model is the core of an ordinary business plan as well. Its assumptions, such as price, volume, hiring and the cost of goods, are stated in a list so that a reviewer who doubts one of them sees its effect on the cash position.
Which letters belong with the plan, and how many?
Letters from customers, partners and investors that confirm interest or funding. DOE accepts up to five letters of support outside the page limit; NIFA and NIH name commitment letters and letters of intent as evidence of financing.
DOE's 2025 specifications introduce a "Limitation of five (5) letters of support (LOS)." The letters are uploaded in the same PDF as the plan and do not count toward its 15 pages.
For USDA applicants the NIFA page lists the forms of Phase III financing evidence: a commitment letter, a letter of intent, a support letter or a specific funding plan. The NIH guide asks for evidence of funding commitments such as letters of commitment or intent.
The NIFA page and the NIH guide name commitment letters and letters of intent, documents in which the writer commits to something. Such a letter states the writer's organization and role, what the writer intends to buy, license or invest, the quantity or amount and the conditions.
How does IAE prepare a business plan for a grant application?
The IAE Secretariat drafts the plan from your materials and open sources; a registry expert in economics and management checks it against 15 points and signs it. A grant plan covers cash flow, break-even, return and risks.
Under the IAE-BP-001 standard the plan runs 25-35 pages in 11 sections, with a five-year financial model in Excel: assumptions listed, a profit and loss statement, monthly cash flow for 24 months, a balance sheet, the break-even point and the use of funds. Market size and growth come from government statistics and dated sources with the name, year and link, sources older than three years are replaced or qualified, and the plan names three competitors.
These are the parts that a commercialization plan draws on: the market analysis, the competition, the team and hiring by quarter, the cash flow and the risks. The agency's format and page limit govern the application itself, so the applicant places the material into the agency's sections, such as DOE's four sections and 15 pages or NIH's 12 pages.
Send a one-page description of the business, the owner's CV, the stage and the purpose through the business plans page. Within one business day the Secretariat replies, free of charge, which plan the purpose requires, which registry expert will check and sign it, the cost and the timeline. The plan takes 7 business days from payment and a full set of documents, 4 on rush, and one round of edits on the comments of the bank or investor is included.
An existing plan can be sent for review: a registry expert checks it against the same 15 points in 3 business days and returns a table of points met, partly met and not met, three main risks and a list of edits by priority. The plan does not guarantee an award; the agency decides.
Sources
- 7 CFR 3403.8, Phase II application, USDA Small Business Innovation Research Grants Program (eCFR)
- USDA National Institute of Food and Agriculture, SBIR/STTR Commercialization Plans
- National Institute on Drug Abuse (NIH), Writing a Good Commercialization Plan: Suggestions for SBIR/STTR Applicants (PDF)
- U.S. Department of Energy, Office of Science, Preparing Your Phase II Commercialization Plan: New P2 CP Specifications (2025, PDF)
Read also
All articles
International Entrepreneur Rule: what must a founder and a start-up show for parole, and where does a business plan fit?
The International Entrepreneur Rule is a parole program in 8 CFR 212.19 and not a visa. A founder who owns at least 10 percent of a U.S. start-up
E-1 treaty trader visa: what must the business show about substantial and principal trade, and what belongs in the business plan?
An E-1 visa needs no investment. It needs trade that already exists: a continuous flow of exchanges between the United States and the treaty country
E-2 visa franchise business plan: what does the franchise disclosure document give the plan, and what must the plan add?
A franchise buyer who applies for an E-2 visa meets the same tests as any other investor: a real and operating enterprise, a substantial investmentBusiness plans for petitions, banks and investors
Send a description of the business
A page about the business, a CV, the stage and the purpose. The expert, the cost and the timeline within one business day, free of charge.

